Ispecimen Inc

This proposal asks shareholders to authorize, under Nasdaq Listing Rule 5635(d), the issuance of shares related to the Company’s May 8, 2026 Securities Purchase Agreement—specifically shares underlying Pre-Funded Warrants and additional shares that could be issued via full-ratchet anti-dilution adjustments, top-up shares, and elected MFN terms—that could collectively exceed the 19.99% Nasdaq cap and potentially be issued at a price below Nasdaq’s Minimum Price. Management is seeking approval because the Purchase Agreement and warrants contain MFN and full-ratchet anti-dilution mechanics that may require issuing additional shares or lowering purchase prices; Nasdaq rules require shareholder approval before such issuances can exceed the 19.99% threshold or be at a sub‑minimum price. Granting approval would allow those contractual adjustment mechanisms to operate as written and avoid potential breaches of the Purchase Agreement, preserving financing certainty for the Purchasers while enabling the Company to meet its obligations. The principal rationale from the Board is to permit the transaction to close and to provide flexibility in implementing elected MFN terms and anti-dilution adjustments. Key risks to existing holders include potentially substantial dilution if subsequent financings trigger full‑ratchet or MFN adjustments, reductions in relative voting power, and downward pressure on the market price of the common stock. The Company frames the financing proceeds as intended for working capital, including marketing, but the proxy cautions that the magnitude of dilution depends on the pricing and structure of any qualifying future financings and the number of Purchasers making MFN elections. From a governance perspective, the proposal shifts the balance toward honoring contractually agreed investor protections (MFN/anti-dilution) at the potential cost of issuer dilution; approval is typical for PIPEs with aggressive anti-dilution/MFN features. The Board unanimously recommends FOR on the basis that approval is required by Nasdaq rules and is necessary to permit the Company to perform under the Purchase Agreement and preserve access to the committed capital.

This proposal requests stockholder authorization to amend the Company’s Certificate of Incorporation to permit the Board to effect a reverse stock split at any ratio between 1:10 and 1:100, with the Board retaining sole discretion over the exact ratio and the timing of the split (if any), effective upon filing the Certificate of Amendment with the Delaware Secretary of State. Management’s stated motivation is to provide a tool to raise the per-share trading price—principally to address Nasdaq’s $1.00 minimum bid requirement and thereby preserve the Company’s listing and liquidity—while allowing the Board to act quickly if share price declines make a reverse split advisable. The proxy also notes the Company’s recent prior splits (1-for-20 in 2024 and 1-for-40 in April 2026) and explains that the Board may abandon the Reverse Split at any time prior to filing, and that if implemented the Board’s authority to effect the split would expire 12 months after the Special Meeting. Potential advantages identified include improved acceptability to institutional investors and market participants and reduced risk of delisting; potential disadvantages include the possibility that the market price will not permanently increase, increased odd-lot holdings and transaction costs for small holders, and the enlarged ability to issue authorized but unissued shares (because authorized shares are not proportionately reduced), which could enable dilution or anti‑takeover effects. The Board emphasizes there is no assurance the Reverse Split will achieve its objectives and that the Company will consider numerous factors (trading history, Nasdaq rules, market conditions, etc.) before acting. The Board unanimously recommends FOR, viewing the authorization as prudent contingency planning to maintain Nasdaq compliance and marketability while retaining discretion to decline to implement the split.

This proposal asks shareholders to pre-authorize, under Nasdaq Listing Rule 5635(d), the issuance of shares upon conversion or exercise of convertible or equity-linked securities that the Company might issue in one or more financings within 12 months, where conversion/exercise pricing could reflect discounts up to 80% off the applicable lowest VWAP (i.e., a 20% floor). Management argues this authorization provides crucial flexibility to access capital when market conditions are poor or other financing options are limited, increasing the Company’s ability to negotiate financings that could be completed on commercially acceptable terms. The Board retains discretion to limit the terms of any financing—by imposing share caps, using smaller discounts or higher floors, fixing conversion prices, or declining to consummate transactions—so shareholder approval does not obligate the Company to use the maximum discount. The primary risk is significant dilution to existing stockholders if variable-priced securities settle at low market prices or if anti‑dilution/MFN features and pricing resets operate, as a low floor multiplies the number of shares issued per dollar raised and could create downward pressure on the trading price. From a governance standpoint this is a common but investor‑sensitive authorization that transfers substantial issuance flexibility to management for a limited period; the Company will still be bound by fiduciary duties and Nasdaq rules and would seek further approvals if required. The proxy makes clear that shareholders will not vote on the final financing terms if they fall within the stated parameters, which increases informational asymmetry and underscores the need for board-level safeguards. The Board unanimously recommends FOR on the basis that the ability to raise capital under difficult conditions outweighs the dilution risk, subject to board oversight and the Company’s discretion to impose tighter terms or abandon financings.

This proposal seeks approval of a milestone‑based acquisition of AI assets and associated IP from Foldlab AI Ltd. for total consideration of $4.5 million (comprised of $2.0 million in cash payable as an upfront payment and two milestone payments, and $2.5 million in stock valued by VWAP), with the Acquisition Shares subject to a 5‑year escrow/lock‑up and voting‑proxy arrangements intended to limit near‑term resale pressure. Management represents the Acquired Assets as two principal AI deliverables (a Disease‑Associated Protein Discovery AI Agent and a Disease Trend Prediction and Monitoring AI Model) together with IP, code, models, weights and supporting materials; closing is conditioned on accuracy of seller reps, delivery of disclosure schedules, Nasdaq listing confirmation for the Acquisition Shares, regulatory consents, and other customary conditions. The Board’s rationale is strategic—integrating AI disease‑analysis capabilities into the Company’s biospecimen marketplace could accelerate product offerings and differentiation—while the milestone structure aligns payments to deliverables and the long escrow seeks to mitigate immediate dilution. Key risks include execution and integration risk for AI products, uncertainty around seller’s limited operating history, the possibility that milestone deliverables are not accepted, and eventual dilution and selling pressure once escrow expires after five years. The proxy highlights indemnities (with certain caps and baskets), transition services, and the private‑placement nature of the Acquisition Shares (restricted legends, no registration obligation), increasing resale constraints for the seller and potentially limiting liquidity of those shares. From a Nasdaq rules perspective, stockholder approval is sought under Rule 5635(a) because the issuance of Acquisition Shares may equal or exceed 20% of outstanding shares; failure to approve would prevent closing. The Board unanimously recommends FOR, viewing the transaction as potentially value‑enhancing while acknowledging material execution and dilution risks.

This proposal authorizes the Board to adjourn the Special Meeting to a later date or dates to permit additional solicitation of proxies if there are not sufficient votes at the time of the meeting to approve Proposals 1–4. Management describes this as a contingency mechanism to ensure that the Company can seek additional shareholder support without reconvening a separate meeting, and the proxy notes the adjournment authority will not extend beyond any date by which the Company may properly adjourn under its charter or Delaware law. The proxy also identifies that Proposal 5 is considered a routine matter for broker discretionary voting (brokers may vote uninstructed shares on adjournment). The main practical effect of approval is to preserve managerial flexibility in achieving quorum or vote requirements for the substantive proposals; rejection could force the Company to seek other avenues to solicit votes or abandon proposals that lack support. The Board unanimously recommends FOR; in practice adjournment votes are commonly approved because they facilitate orderly ballot completion and legitimate additional solicitation when needed, and they do not themselves change substantive rights or terms of the other proposals.